Posted by Michael Wonder on 02 May 2018
Health Canada approves Kisqali for the treatment of HR-positive and HER2-negative metastatic breast cancer in post-menopausal women in combination with letrozole as an initial endocrine-based therapy
2 May 2018 - Arrival of new first-line therapy provides additional option for those living with this advanced form of breast cancer.
Novartis Pharmaceuticals Canada is pleased to announce that Health Canada has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (letrozole) for the treatment for hormone receptor HR-positive, human epidermal growth factor receptor 2 HER2-negative advanced or metastatic breast cancer as initial hormone-based therapy for post-menopausal women.
The approval is based on results from the pivotal MONALEESA-2 trial, which included eight Canadian trial sites, and 32 Canadian investigators.
